Key facts
- This page summarizes Michael Auerbach's Form 4 filing for ATAI Life Sciences N.V. (ATAI).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 14 Jun 2024, 17:00.
Michael Auerbach - 13 Jun 2024 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)
- Reporting relationship
- Director
- Issuer ticker
- ATAI
- Reported as of
- 13 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2024, 17:00:46 UTC
- Prior SEC filing
- 10 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ryan Barrett, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Auerbach filed Form 4 for ATAI Life Sciences N.V. (ATAI) on 14 Jun 2024.
Change
- Previous filing in this sequence was filed on 10 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATAI
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +103,000
- Change %
- Price
- $0.000000
- Shares after
- 103,000
- Date
- 13 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 103,000
- Exercise price
- $1.34
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 13, 2025.